INTRODUCTION
Targeted therapies (TT) have significantly improved the prognosis of m-ccRCC-patients. Sunitinib is a TKI targeting vascular-endothelial-growth-factor-receptor (VEGFR) that significantly prolongs PFS, but not OS, as compared to Interferon-alpha(1, 2). Currently, it is an approved first-line treatment option for m-ccRCC-patients. However, in the pivotal phase III trial 7% of patients experience progressive disease (PD) upon RECIST at their first evaluation and virtually all patients ultimately develop PD (2) .
In routine clinical practice, primary PD rate is higher and may reach 20%. Although several prognostic factors of survival in m-ccRCC-patients receiving TT have been described and several resistance mechanisms have been proposed (3) , no reliable biomarkers of sunitinib sensitivity or primary/secondary resistance have been identified.
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MATERIAL AND METHODS
Included patients
Primary ccRCC-specimens were collected from 121 patients undergoing nephrectomy in 19 French and one Belgian hospitals from 1994 to 2011 (patients characteristics in Table_S1). For inclusion in the study, patients had to have developed synchronous or metachronic metastases, received sunitinib (50mg/day, four weeks-on/two weeks-off) as first-line treatment in the metastatic setting (prior cytokine therapy was allowed), completed at least one 28-day cycle of sunitinib, and undergone their first CTscan assessment.
Drug schedule and dose-reduction policy complied with local practice guidelines. Follow-up chest/abdomen CT-scans were performed every 2 cycles of treatment. Study endpoints were RR according to RECIST 1.0, PFS and OS. Four expert genitourinary pathologists blinded to patient outcome reviewed all nephrectomy pathology slides. The protocol was approved by the medical ethics review boards of all participating institutions. Signed consent was obtained from all patients in accordance with French and Belgian legislations. Frozen biological material from deceased patients was used when prior agreement for such use had been given by the institutional review board.
Data sets and preprocessing
Transcriptome data:
Transcriptomic profiling was performed using HuGene 1.0ST Affymetrix array for 53 ccRCC-samples and 6 adjacent normal tissue samples (NTs). Biotinylated single strand cDNA targets were prepared with 200ng of total RNA, using the Ambion WT Expression Kit the GeneChip® WT Terminal Labeling Kit according to Affymetrix recommendations.
Methylome data:
Whole-genome DNA methylation was analyzed in 102 ccRCCs and 5 adjacent NTs using the Illumina Infinium HumanMethylation450 assay that examines the DNA methylation status of 485.000 CpG sites (covering 99% of RefSeq genes and 96% of CpG islands).Genomic DNA was extracted using either 6
Genome data:
For chromosome gain/loss profiling, 103 ccRCCs and 5 adjacent NTs were analyzed with Illumina OmniExpress chips, containing 731.442 probes. Hybridization was performed by IntegraGen (Evry, France), according to the manufacturer's instructions. The absolute copy numbers and genotype status of segments were determined using the Genome Alteration Print (GAP) method (14) . Segments with an absolute copy number above (resp. below) the ploidy of the sample were considered as gains (resp. losses). The Genomic Identification of Significant Targets In Cancer (GISTIC) methodology (15) was used to identify significantly recurrent chromosome aberrations.
Quantitative RT PCR (qRT-PCR):
qRT-PCR reactions were performed on 98 ccRCCs and 5 NTs with Low Density Array (LDA) for 65 genes and individual probes for 5 genes as previously described (16) . Genes were selected from the differential analysis of the Affymetrix data (anova q-value less than 0.05 and an absolute Fold change greater than 1.5). Primers and probes for all genes were obtained from Applied Biosystems Taqman Gene Expression Assays. Table_S2 provides the gene symbol, gene name and Applied Biosystems Assay ID-number for the genes studied.
For details on overlap between samples used for each omics, see Table_S3.
Mutation analysis
Tumors were screened for VHL and PBRM1-mutations (Table_S4) using direct sequencing (Primers and protocols available on request).
Omics Analysis
Unsupervised classification: For unsupervised class discovery within the four omics, three methods were used: the Recursively Partitioned Mixture Model (RPMM) (17) and two consensus clustering methods (18, 19) . Only the results obtained with the third method were described in the paper.
Nevertheless, we showed a strong association between the three methods (Fisher-exact p-values from 3.9e-19 to 2.92e-21). We used the gap statistic to determine the number of clusters (20) .
Differential Analysis:
We used moderate T-tests to identify genes differentially expressed between groups of samples, using limma R-package. Anova-models were used for multigroup comparison. To control for multiple testing we measured the local false discovery rate using the Benjamini and Hochberg method (R-package stats).
Research. 
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Association analysis: We evaluated the association between unsupervised or supervised subgroups and the bioclinical factors using chi-squared or Fisher-exact tests. For each clinical characterization all covariates were analyzed but only the significant covariates were shown (p<0.05). The bioclinical factors included TNM, ECOG-PS, IMDC-, Fuhrman-or MSKCC-scores, systemic treatment, hemoglobin (<11.5 g/dl in women, <13.0 g/dl in men), platelets (>400.000/mm³), LDH (>1.5x Upper Limit of Normal), neutrophils (>4.500/mm³), calcium (>10 mg/dl), pathological characteristics such as eosinophils, necrosis or inflammation, rhabdoid and sarcomatoid phenotypes.
Chi-squared or Fisher-exact tests were used to select the recurrent chromosome aberrations identified by GISTIC that are differential between groups. Criteria of sensitivity and specificity were added to select aberrations characteristic of a given subgroup. An aberration was characteristic of a given subgroup if the sensitivity and the specificity are >0.65.
Signaling pathway analysis:
To identify biological features associated with ccRCC molecular subtypes, 17.306 pathways collected from KEGG, GO, MSigDB, SMD and Biocarta (and related genes) were tested. A hypergeometric test was used to measure the association between a gene (probe set) list -related to a given molecular subtype (see below)-and a biological pathway or a gene ontology term (GO term), as in GOstats R-package from R. Gentleman. Pathway analyses were performed on transcriptome data, methylome data and methylome data anti-correlated with transcriptome data (correlation test p<0.05 and correlation coefficient <0). In this pathways analysis, the gene lists related to each molecular subtypes corresponded to (i) genes specifically up-regulated in the subtype (resp. hypermethylated), (ii) genes specifically down-regulated in the subtype (resp. hypomethylated) and (iii) genes both up and down-regulated (resp. hyper and hypomethylated) in the subtype.
Survival analysis: Survival time was calculated from the first sunitinib treatment. Patients who were lost to follow-up or alive at the time of the study were treated as censored events. Survival curves were calculated according to the Kaplan-Meier method (function Surv, R-package survival, V2.29) and differences between curves were assessed using the log-rank test (function survdiff, R-package survival).
To find clinical criteria related to PFS or OS, univariate models were performed on all the pathological and clinical covariates (function coxph, R-package survival). Covariates showing a significant association to prognosis (logrank p<0.05) at the univariate level were selected to be analyzed in multivariate models, after the exclusion of redundant covariates (ex MSKCC-and IMDC-scores). 
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A first centroid based predictor was built to assign a sample to one of the three following groups ccrcc1&4/ccrcc2/ccrcc3 using a subset of the differentially expressed genes between these three groups. A gene was defined differentially expressed in a subtype when the anova p-value was <0.05 and when the absolute fold change with the other subtypes was >0.5. The optimal subset of 27 genes was obtained by a step by step strategy by optimizing the success rate. The DLDA-dissimilarity measure was then used to predict the subtype(Table_S2).
For samples predicted as ccrcc1&4 (using the predictor mentioned above), a second centroid-based predictor was built to assign each sample to one of the two subtypes ccrcc1 or ccrcc4. A subset of the differentially expressed genes between ccrcc1-and ccrcc4-subtypes was used. A gene was defined differentially expressed between the two subtypes when the anova p-value was <0.05 and when the absolute fold change was >3. The optimal subset of 8 genes was obtained by a step by step strategy by optimizing the success rate. The DLDA-dissimilarity measure was then used to predict the subtype.
The obtained centroid-based predictors were applied on two public datasets: The Brannon expression dataset (GEO-website, GSE33093)(5) and TCGA-dataset(6).
Use of immune metagenes
The datasets mentioned by Bindea and collaborators were downloaded and normalized separately using the fRMA Bioconductor package (21) . Cancer cell lines dataset GSE5720 was also retrieved from Gene Expression Omnibus and normalized using fRMA. Samples GSM133550, GSM133594, GSM133638, GSM133657, which correspond respectively to ccRCC cell lines ACHN, SN12C, UO-31, Caki-1, were added. All probesets identified included in the five metagenes used in our work (NK CD56dim, Cytotoxic cells, T-cells, B-cells, Macrophages) were checked for expression by kidney cancer cell lines. 138/142 probesets were completely specific and sensitive to predict Immune celltype against ccRCC cell lines samples, and 134/142 probesets had a right-tailed t-test p-value<0.05 when compared to ccRCC cell lines samples. To compute average metagene values in our dataset, log2 expression values for each probesets were first mapped to gene symbols using average expression of all the corresponding probesets, then this value was centered and scaled across our dataset. Finally, the mean of all the scaled expressions was taken to represent the signature.
Immunohistochemistry:
5-μm formalin-fixed and paraffin-embedded tissue sections were stained with an anti-CD8 (5.0µg/ml, clone SP16, Springbioscience) with an autostainer Link 48 (Dako) as previously described (22) .
Deparaffinization, rehydration and epitope retrieval was performed in a PT-Link (Dako) in a High pH- 
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Springbioscience) and posteriorly with a biotin-streptavidin coupled antibody. Revelation was done with 3-amino-9-ethylcarbazole substrate (Vector Laboratories).
RESULTS
Patient Characteristics and Clinical Predictors of sunitinib Response
In our series of 121 patients, after a median follow-up of 55 months (range 1.5-86), median PFS and OS were 13 and 27 months, respectively. 47% of patients experienced a complete or partial response (CR/PR), 36% Stable disease (SD) and 17% early PD following RECIST 1.0. By comparing patients with extreme phenotype (CR/PR versus PD), we identified several clinical and biological features associated with a poor sunitinib response: baseline neutrophilia, thrombocytosis, anemia, sarcomatoid differentiation, synchronous metastases at initial diagnosis, poorer ECOG-PS, Heng-(23) and MSKCCscores (24, 25) (Figure_1A&B). However, in the overall series of patients, using all the clinical, pathological and molecular features and a variety of predictive algorithms (PAM, DLDA, DQDA), supervised analyses failed to identify robust factors predictive of sunitinib response(Table_S5). As this result could be due to the molecular diversity of the tumors, we investigated the relationships between ccRCC molecular subtypes and response to sunitinib.
Molecular subtypes and sunitinib response
Using the expression profiles of the 1% most variable probe sets (n=324 representing 294 different genes) among the whole series of tissues (53 ccRCCs, 6 NTs), we performed an unsupervised consensus clustering analysis of our series. We identified four robust subgroups of tumors, called ccrcc1 to ccrcc4 (Figure_2). In particular, ccrcc3-tumors included all NTs and showed a transcriptomic signature closed to normal samples (Figure_2B+2C).
To extend the molecular subtyping to a larger series, we built a qRT-PCR 35-genes classifier (Table_S6), which correctly classified 94% of the samples from the initial series in ccrrc1-4, and was used to predict 47 additional ccRCC-tumors.
In the series of 98 patients, non-responders were enriched in ccrcc1 (PD 22%) and ccrcc4 (27%) versus 3 and 0% in ccrcc2 and ccrcc3, respectively (Figure_3A)(Table_S7). In contrast, responders were over-represented in ccrcc2 (PR/CR 53%) and ccrcc3 (70%) compared to 41% and 21% in ccrcc1 and ccrcc4, respectively (p=0.005)(Figure_3A)(Table_S7). Moreover, ccrcc1 and ccrcc4-tumors showed a poorer PFS (13, 8, 19 and 24 months, respectively; p=0.0003) and OS (24, 14, 35 and 50 months, respectively; p=0.001) compared to ccrcc2 and ccrcc3-tumors(Figure_3B)(Table_1) (Table_S7). Classification of the tumors recoded in ccrcc1&4 versus ccrcc2&3 was the most significant covariate in univariate cox analysis with a poorer PFS (p=0.004) and OS (p=0.0002). For the multivariate analysis, in a first step, among all the factors that were associated with PFS and OS in univariate analysis, we excluded those factors that could be overlapping(Table_1). Finally, the following factors were included in the multivariate analysis, both for PFS and for OS: IMDC-score, the presence of bone metastases, the presence of sarcomatoid dedifferentiation, 8q-amplification and the 
classification recoded as ccrcc2+3 versus ccrcc1+4. It remained the only significant covariate in the multivariate cox-model for PFS (p=0.017). In the multivariate cox-model for OS, the recoded classification (p=0.0064) and the presence of bone metastasis (p=0.049) remained as significant covariates (Figure_3C) .
Characterization of the m-ccrcc molecular subtypes
To better understand how each molecular subtype could influence response to sunitinib, we characterized our cohort for somatic mutations in PBRM1-and VHL-genes (n=117 tumors), methylation profiling exploring 485,000 nucleotide sites (n=102) and copy number targeting 731,442 genomic loci (n=103). Transcriptome and methylome profiles of the four subtypes were compared using pathway analysis methods and recurrent copy number aberrations were delimited from the SNP- In ccrcc2-tumors, the "cellular response to hypoxia" pathway was less activated than in the ccrcc1/ccrcc4-subtypes(Figure_4B).
Based on these molecular characteristics, we renamed our subtypes as follows: ccrcc1="c-myc-up", ccrcc2="classical", ccrcc3="normal-like" and ccrcc4="c-myc-up and immune-up"(Table_2).
Validation using the TCGA dataset
We further predicted our four subtypes in the public TCGA-samples(Figure_S7)(6) with our 35-genes classifier(Table_S6). Like in our series, ccrcc3-tumors showed 'normal-like' transcriptome and methylome profiles. Somatic PBRM1-mutations were most frequently identified in ccrcc1/ccrcc2-tumors but rarely found in ccrcc3/ccrcc4-tumors. In both series, somatic VHL-mutations were more frequently distributed in ccrcc1/ccrcc2-tumors. The BAP1 and SETD2 mutations (data not available in our series) also showed association with the molecular subtypes: BAP1 was most mutated in the ccrcc4-tumors (p-value = 0.0098) and SETD2 was most mutated in the ccrcc1-tumors (p-value =0.06). 
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DISCUSSION
Our multi-omics analysis revealed that molecular tumor subtypes are germane to predict response, PFS and OS, in m-ccRCC patients treated with sunitinib. We identified 4 robust molecular subgroups of ccRCCs based on mRNA expression data. ccrcc3-('normal-like') and ccrcc2-tumors ('classical') showed better sunitinib responses than ccrcc1-('c-myc-up') and ccrcc4-tumors ('c-myc-up and immune-up'). The ccrcc4-subtype was associated with the poorest sunitinib response. Subtype classification was the only significant covariate in multivariate analyses for PFS and OS. Survival was significantly longer for ccrcc2/ccrcc3 compared to ccrcc1/ccrcc4.
Comparison with previous ccRCC molecular classifications, showed a high correlation of our four ccrcc-groups with the three groups ccA, ccB and cluster_3 described by Brannon(4, 5)(Table_S10). In particular, ccrcc3-tumors shared several characteristics of cluster_3 (5); it included all NTs and showed a transcriptomic signature closed to normal samples(Figure_2B+2C). Although the series of Brannon et al. and the TCGA included both patients that were cured with nephrectomy alone as well as patients that eventually reached the metastatic setting, while in our series only patients with metastatic disease were included, our subgroups are tightly related to the previously identified classification with an overrepresentation of the poor prognosis ccB-group and its refinement in two subgroups, ccrcc1 and ccrcc4. Subtypes were identified using a 35-gene signature that could be useful in future tumor screening. Given the important and significant difference in RR, this classification has both predictive and prognostic potential in sunitinib-treated m-ccRCC patients.
The incidence of VHL-mutations was lower than the reported incidence in literature of 55-60% in sporadic ccRCCs. VHL-disease-associated ccRCCs seem to grow more slowly and are associated with an overall better prognosis than sporadic ccRCCs. Sporadic ccRCCs that lack functional VHLprotein might, therefore, be expected to have a better prognosis than sporadic ccRCCs resulting from VHL-independent mechanisms of pathogenesis. Some studies seem to support this hypothesis (26, 27) , although others have found no association between the presence or absence of VHL-alterations and prognosis or adverse clinical and pathological features.
The ccrcc1/ccrcc4-subtypes, which were more closely linked with non-responders to sunitinib, shared common molecular characteristics such as up-regulation of MYC-targets or a hypermethylated status strongly correlated with a polycomb stem-cell phenotype.
However, ccrcc4-tumors showed specific pathological features such as a more inflammatory and sarcomatoid phenotype, an up-regulation of cellular immune pathways and an omnipresent 8q21.13- shorter PFS than patients with non-hypoxic targets (36) . Thus, the balance of neo-angiogenesis versus hypoxia could be a major trigger of response to anti-VEGF-TT (37) .
In a first step, as we worked on a limited number of patients, our findings should be validated in an independent patient cohort. Once validated, this molecular subtyping of tumors could probably help treatment personalization. Since patients with ccrcc4-tumors have a short PFS under sunitinib treatment, hypomethylating agents targeting epigenetic defects (38) Univariate models were performed on all the pathological and clinical covariates. Only significant covariates in any of the two analyzes are indicated. Continuous variables are annotated '-' in the 'value' column.
For the multivariate analysis, in a first step, among all the factors that were associated with PFS and OS in univariate analysis, we excluded those factors that could be overlapping. For instance, IMDC (Heng) score and MSKCC score are redundant. We preferred IMDC (Heng) score, because the pvalues were more significant for PFS and OS in univariate analysis. As ECOG PS and neutrophil count are part of the IMDC (Heng) score, they were excluded. As all tumors with sarcomatoid dedifferentiation were classified Fuhrman grade 4, we only retained sarcomatoid dedifferentiation. As a consequence, the following factors were included in the multivariate analysis, both for PFS and for OS: IMDC (Heng) score, the presence of bone metastases, the presence of sarcomatoid dedifferentiation, 8q-amplification and the classification recoded as ccrcc2+3 versus ccrcc 1+4. 
